REM-422, a first-in-class MYB mRNA degrader, induces regression across multiple preclinical models of ACC Watertown, Mass. (October 16, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, will deliver a poster presentation demonstrating the therapeutic potential of REM-422, a potent, selective, […]